Fig. 6
From: Microbial metabolite sensor GPR43 controls severity of experimental GVHD
NLRP3 deficiency in non-hematopoietic cells exacerbates GVHD and is not rescued by propionate. B6 WT and Gpr43−/− mice received BMT from either syngeneic B6 or allogeneic BALB/c donors. a Representative immunoblots and densitometric analysis of NLRP3 normalized to the presence of β-actin in IECs (CD326+) from allogeneic recipients 14 days after BMT (n = 3 each, two-tailed Mann–Whitney U test). b IL-18 production by colon and ileum explant culture from WT B6 and Gpr43−/− mice stimulated overnight with MSU as measured by ELISA (n = 6 each, two-tailed unpaired t-test). c, d Chimeric [B6Ly5.2 → B6] and [B6 Ly5.2 → Nlrp3−/−] animals received BMT from either syngeneic WT B6 or allogeneic BALB/c donors. Survival and clinical GVHD score after BMT (n = 6 syngeneic each, n = 7 allogeneic [B6Ly5.2 → B6], n = 14 [B6 Ly5.2 → Nlrp3−/−], log-rank test for survival, two-tailed Mann–Whitney U test for GVHD Score) are depicted. Data are pooled from two experiments. e, f Chimeric [B6Ly5.2 → B6] and [B6 Ly5.2 → Nlrp3−/−] animals after BMT were treated with vehicle, butyrate (10 mg kg−1 per day) or propionate (15 mg kg−1 per day). Survival and clinical GVHD score after BMT (n = 6 syngeneic, n = 10 Vehicle, n = 5 Butyrate and Propionate each, log-rank test for survival, two-tailed Mann–Whitney U test for GVHD Score). Data are pooled from two experiments. *P < 0.05, **P < 0.01, ***P < 0.001, error bars show the mean ± s.e.m.
